Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | ALEXANDER: bicistronic CD19 & CD22 CAR for DLBCL

Wendy Osborne • 1 Jun 2020
EHA 2020
Diffuse Large B-Cell Lymphoma Lymphoma Antibodies AUTO3 CAR-T Pembrolizumab
ALEXANDER

Wendy Osborne, MBBS (Hons), MRCP, FRCPath, Freeman Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK, discusses the Phase 1 Alexander study (NCT03287817) of AUTO3, the first bicistronic chimeric antigen receptor (CAR) targeting CD19 and CD22 with pembrolizumab in patients with relapsed/refractory diffuse large b-cell lymphoma (DLBCL). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Wendy Osborne

2:03
Novel treatment approaches for early-stage DLBCL
Wendy Osborne • 24 Apr 2023
1:20
Improving patient outcomes in CTCL: clinical collaboration and novel agents
Wendy Osborne • 24 Apr 2023
2:19
Session highlights: autoSCT in T-cell lymphoma, classification updates and fertility preservation
Wendy Osborne • 24 Apr 2023
1:01
Pitfalls in the diagnosis of lymphoid malignancies: interpreting PET scans
Wendy Osborne • 24 Apr 2023

Related Videos

1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
2:28
Checkpoint inhibitors vs brentuximab vedotin as salvage therapy prior to alloSCT for HL
Jacopo Mariotti • 15 Apr 2024
1:37
Exciting CAR-T clinical trials in LBCL and FL
Gloria Iacoboni • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals